HIGHLIGHTS
- who: Angelo Maffei et al. from the Department of Angiocardioneurology and Translational Medicine, IRCCS Neuromed, Pozzilli, ItalyDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy have published the research work: PI3Kinases in Diabetes Mellitus and Its Related Complications, in the Journal: (JOURNAL)
- how: The specific PI3K β antagonist AZD6482 was tested for its ability to reduce platelet adhesion and aggregation in human volunteers in whom AZD6482 showed its efficacy in inhibiting platelet function without any important effect on insulin sensitivity .
SUMMARY
Fighting diabetes_mellitus has therefore become a priority. On this issue . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.